Results 41 to 50 of about 26,004 (264)
Translational Oncology, 2018 Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is
Md Sazzad Hassan +6 more
doaj +1 more source
Evaluation of the Clinical Outcome of Nab-paclitaxel on Multiple Primary Malignancies: A Systematic Review and Meta-analysis [PDF]
International Journal of Scientific Research in Dental and Medical Sciences, 2022 Background and aim: In the present study, an attempt has been made to analyze the side effects of nab-paclitaxel compared to sb-paclitaxel and docetaxel.
Fatemeh Salehi Kahrizsangi +4 more
doaj +1 more source
Dermatology Practical & Conceptual, 2015 Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]—used in the treatment of lung, breast, and head and neck cancers—have been associated with cutaneous adverse effects, including photodermatoses.
Bryce D. Beutler, Philip R. Cohen
doaj +1 more source
Afatinib use in recurrent epithelial ovarian carcinoma. [PDF]
, 2019 •Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 ...
Alvarez, Edwin A +3 more
core +1 more source
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study [PDF]
, 2019 BACKGROUND: Only a few patients with pancreatic ductal adenocarcinoma (PDAC) recurring after curative resection and peri-operative (neoadjuvant and adjuvant) therapy are included in clinical trials of metastatic PDAC.
Gbolahan, Olumide B. +4 more
core +1 more source
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer [PDF]
, 2017 Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the ERK ...
Awasthi, Niranjan +4 more
core +1 more source
Качественная клиническая практика, 2020 Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the ...
A S Kolbin +4 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2022 Background Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated. Here, we aim to reveal the underlying mechanisms of nanoparticle albumin-bound paclitaxel (nab-paclitaxel ...
Mengxuan Zhu +8 more
doaj +1 more source
Current Oncology, 2021 We investigated first-line (1L) treatment patterns and predictors of taxane use to better understand the evolving metastatic triple-negative breast cancer (mTNBC) treatment landscape.
Joyce O’Shaughnessy +8 more
doaj +1 more source
The role of taxanes in triple-negative breast cancer: literature review [PDF]
, 2015 Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs.
DE LAURENTIIS, MICHELINO +1 more
core +1 more source